Invesco Ltd.

NYSE:IVZ Stock Report

Market Cap: US$7.8b

Invesco Valuation

Is IVZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IVZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IVZ ($17.41) is trading below our estimate of fair value ($24.05)

Significantly Below Fair Value: IVZ is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IVZ?

Key metric: As IVZ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IVZ. This is calculated by dividing IVZ's market cap by their current revenue.
What is IVZ's PS Ratio?
PS Ratio1.3x
SalesUS$5.89b
Market CapUS$7.76b

Price to Sales Ratio vs Peers

How does IVZ's PS Ratio compare to its peers?

The above table shows the PS ratio for IVZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.2x
JHG Janus Henderson Group
3x1.3%US$6.9b
AMG Affiliated Managers Group
2.8x1.4%US$5.5b
SEIC SEI Investments
5x5.3%US$10.2b
CNS Cohen & Steers
10.1x9.3%US$5.1b
IVZ Invesco
1.3x-4.8%US$7.8b

Price-To-Sales vs Peers: IVZ is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (5.2x).

Price to Sales Ratio vs Industry

How does IVZ's PS Ratio compare vs other companies in the US Capital Markets Industry?

24 CompaniesPrice / SalesEstimated GrowthMarket Cap
SNEX StoneX Group
0.03xn/aUS$3.09b
OPY Oppenheimer Holdings
0.5xn/aUS$620.50m
BKKT Bakkt Holdings
0.1x-150.0%US$398.74m
MKTW MarketWise
0.06x-3.5%US$179.03m
IVZ 1.3xIndustry Avg. 3.2xNo. of Companies24PS03.26.49.612.816+
24 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IVZ is good value based on its Price-To-Sales Ratio (1.3x) compared to the US Capital Markets industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is IVZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IVZ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio2x

Price-To-Sales vs Fair Ratio: IVZ is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IVZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$17.41
US$19.09
+9.7%
6.2%US$22.00US$17.50n/a16
Nov ’25US$17.78
US$18.97
+6.7%
6.2%US$22.00US$17.50n/a16
Oct ’25US$17.25
US$17.52
+1.5%
6.1%US$20.00US$16.00n/a16
Sep ’25US$17.09
US$17.53
+2.6%
5.7%US$20.00US$16.00n/a15
Aug ’25US$16.82
US$17.29
+2.8%
6.3%US$20.00US$16.00n/a14
Jul ’25US$14.85
US$16.71
+12.6%
7.0%US$19.50US$15.00n/a14
Jun ’25US$15.71
US$16.70
+6.3%
7.0%US$19.50US$15.00n/a14
May ’25US$14.34
US$16.70
+16.4%
7.0%US$19.50US$15.00n/a14
Apr ’25US$16.49
US$17.80
+7.9%
7.8%US$21.00US$16.00n/a15
Mar ’25US$15.53
US$17.82
+14.7%
7.7%US$21.00US$16.00n/a15
Feb ’25US$16.08
US$17.68
+10.0%
8.7%US$21.00US$15.00n/a15
Jan ’25US$17.84
US$15.64
-12.3%
12.2%US$20.00US$13.00n/a14
Dec ’24US$14.86
US$14.75
-0.7%
7.0%US$17.00US$13.00n/a14
Nov ’24US$13.07
US$14.71
+12.6%
7.3%US$17.00US$13.00US$17.7814
Oct ’24US$14.52
US$17.52
+20.6%
7.6%US$21.00US$15.75US$17.2514
Sep ’24US$16.03
US$17.82
+11.2%
6.8%US$21.00US$16.00US$17.0914
Aug ’24US$16.83
US$17.82
+5.9%
6.8%US$21.00US$16.00US$16.8214
Jul ’24US$16.81
US$17.71
+5.4%
9.0%US$21.00US$15.00US$14.8514
Jun ’24US$14.74
US$17.80
+20.8%
8.9%US$21.00US$15.00US$15.7114
May ’24US$16.78
US$17.96
+7.1%
8.4%US$21.00US$15.00US$14.3414
Apr ’24US$16.40
US$18.07
+10.2%
8.2%US$21.00US$15.00US$16.4914
Mar ’24US$17.53
US$18.25
+4.1%
8.8%US$21.00US$14.50US$15.5314
Feb ’24US$18.92
US$18.04
-4.7%
8.4%US$21.00US$14.50US$16.0814
Jan ’24US$17.99
US$17.21
-4.3%
16.4%US$22.00US$11.50US$17.8414
Dec ’23US$19.43
US$15.69
-19.2%
17.5%US$22.00US$11.50US$14.8613
Nov ’23US$15.56
US$15.00
-3.6%
13.1%US$19.00US$11.50US$13.0713

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

VEF

SEK 2.2b

A venture capital firm specializing in early venture, emerging growth and growth capital investments.

VEFF.F

SEK 0.20

7D

0%

1Y

n/a

Federal Home Loan Mortgage

US$10.4b

Operates in the secondary mortgage market in the United States.

FMCC

US$2.92

7D

0%

1Y

358.8%

ORIX

JP¥3.8t

Provides diversified financial services in Japan, the United States, Asia, Europe, Australasia, and the Middle East.

IX

JP¥106.82

7D

-0.9%

1Y

17.5%